Today: 10 November 2025
Subscribe
Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025
 ·  ·  ·  ·  ·  · 

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

by
9 November 2025
  • Financing wraps up: BMS priced €5 billion of senior unsecured notes in five tranches; closing is expected Monday, Nov. 10. Proceeds will help fund a multi‑tranche debt tender offer that runs to Dec. 3 (early tender Nov. 17). [1]
  • Legal overhang addressed: A $239 million settlement of a long‑running class action tied to legacy Celgene disclosures was filed Nov. 5; it requires court approval. [2]
  • Partner cash already flowing:BioNTech lifted its 2025 revenue guidance after receiving initial payments from the new BMS immuno‑oncology alliance. [3]
  • Data weekend for Camzyos: At AHA Scientific Sessions (Nov. 7–10), BMS is presenting long‑term and real‑world data for Camzyos (mavacamten) in obstructive HCM. [4]
  • Competitive & generic currents: A fresh generic approval for dasatinib (Sprycel) landed Nov. 7, and a startup raised funding to challenge Camzyos in HCM. [5]

Financing & balance sheet: euro notes + tender offer

Bristol‑Myers Squibb priced €5 billion in senior unsecured notes across five tranches — €750M 2030 (2.973%), €1.15B 2033 (3.363%), €1.15B 2038 (3.857%), €750M 2045 (4.289%), and €1.2B 2055 (4.581%) — with closing anticipated Nov. 10, 2025. The notes are guaranteed by Bristol‑Myers Squibb Company. [6]

Proceeds, plus about $3B in cash, are earmarked to fund BMS’s cash tender offers for multiple outstanding dollar notes. The offers expire Dec. 3, 2025 (early tender Nov. 17), with maximum aggregate purchase prices of $4B (Pool 1) and $3B (Pool 2) excluding accrued coupons. [7]

Why it matters: With near‑term maturities and higher‑coupon legacy debt, the pair of transactions gives BMS flexibility to reprofile liabilities while it invests behind late‑stage assets and partnerships.

Litigation: Celgene class action settlement filed

On Nov. 5, BMS agreed to a $239 million settlement resolving claims that Celgene misled investors about prospects for Otezla and ozanimod (Zeposia) ahead of BMS’s 2019 acquisition. After fees, about $159.3 million could go to the class, pending court approval. BMS denied wrongdoing; the settlement removes a legal distraction. [8]

Pipelines & data catalysts: cardio this weekend, cell therapy next

  • Camzyos at AHA 2025 (Nov. 7–10): BMS is showcasing an extension study approaching 4 years and multiple real‑world analyses (including U.S. REMS data) in obstructive HCM, plus updates from the milvexian collaboration with J&J in thrombosis. Today (Nov. 9) sits in the middle of the meeting; additional Camzyos‑related presentations run through Monday, Nov. 10. [9]
  • Breyanzi (liso‑cel) — upcoming FDA decision: The sBLA in marginal zone lymphoma is under Priority Review with an action date of Dec. 5, 2025, a near‑term regulatory catalyst. [10]
  • Sprycel (dasatinib) pressure: The FDA approved generic dasatinib tablets (multiple strengths) on Nov. 7, adding to competitive intensity in CML/ALL and underscoring the importance of BMS’s “new product” cohort offsetting LOE headwinds. [11]

Partner ecosystem: BioNTech payments arrive; new solid‑tumor experiment

  • BioNTech collaboration: BioNTech raised 2025 revenue guidance to €2.6–€2.8B after receiving initial payments from BMS tied to their bispecific PD‑L1/VEGF program (pumitamig/BNT327), with more studies slated in 2026. This follows BMS’s commitment of up to $11.1B in total economics earlier this year. [12]
  • Dispatch Bio clinical‑supply deal: BMS will supply ide‑cel (Abecma) for Dispatch Bio’s planned Phase 1 U.S. study in solid tumors starting 2026 — a first‑of‑its‑kind clinical‑supply pact using an autologous CAR‑T in combination with a tumor‑targeting viral approach. [13]

Earnings context: Q3 scorecard sets the stage

Just ahead of this week’s financing, BMS beat Q3 revenue and EPS expectations, helped by Opdivo (including initial subcutaneous uptake) and Eliquis, while the “growth portfolio” offset steep Revlimid erosion. Headline figures: Revenue $12.22B (vs. $11.8B est.), adj. EPS $1.63; Opdivo $2.53B (+$67M from SC launch), Eliquis $3.75B. [14]

Competitive notes to watch

  • Hypertrophic cardiomyopathy:Braveheart Bio raised $185M (Nov. 5) to advance an HCM therapy licensed from Hengrui, aiming to challenge Camzyos — a reminder that Camzyos’s lead will face follow‑on entrants. [15]

Dates & deadlines (all in 2025)

  • AHA Scientific Sessions: Nov. 7–10 (Camzyos & milvexian data). [16]
  • €5B notes closing:Nov. 10 (expected). [17]
  • Debt tender offers: Early tender Nov. 17; final expiration Dec. 3. [18]
  • FDA action date — Breyanzi (MZL):Dec. 5. [19]

Bottom line

On November 9, 2025, Bristol‑Myers Squibb sits at the intersection of capital structure cleanup (euro notes + tender), pipeline proof points (Camzyos at AHA; Breyanzi PDUFA next), and partner‑powered momentum (BioNTech payments starting to hit). Legal risk is reduced via the Celgene settlement filing, while generic and competitive pressures reinforce why BMS is leaning into late‑stage assets and alliances. Near‑term investor focus: notes closing Monday, tender early‑tender participation, and Dec. 5 FDA outcome for Breyanzi. [20]

This article is for information purposes only and is not investment advice.

This $46 Stock Could Hit $70 in 2025! (Undervalued Pharma Giant)
Watch this video on YouTube.

References

1. news.bms.com, 2. www.reuters.com, 3. www.reuters.com, 4. news.bms.com, 5. www.onclive.com, 6. news.bms.com, 7. news.bms.com, 8. www.reuters.com, 9. news.bms.com, 10. www.pharmexec.com, 11. www.onclive.com, 12. www.reuters.com, 13. www.businesswire.com, 14. www.reuters.com, 15. www.biopharmadive.com, 16. news.bms.com, 17. news.bms.com, 18. news.bms.com, 19. www.pharmexec.com, 20. news.bms.com

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

  1. ARCC Stock Today: Ares Capital’s 9.5% Dividend, Q3 Record NAV, and Fresh Insider Buying (Nov. 9, 2025)
  2. Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025
  3. Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead
  4. HIVE Digital Technologies (NASDAQ: HIVE) news today — Nov. 9, 2025: Earnings date locked, 23 EH/s milestone, and AI data‑center expansion

Stock Market Today

  • Starbucks (SBUX) Valuation After Recent Share Price Rebound
    November 9, 2025, 6:04 PM EST. Starbucks (SBUX) stock has rebound to about $85.57 after a ~9% monthly gain, with a 1-year total return still in the red. A fair value of $94.17 supports an UNDERVALUED call as investors weigh a path to an operational recovery and top-line growth. The narrative emphasizes the Back to Starbucks/Green Apron initiatives, store restructuring, and cost reductions, plus growth in markets-especially China-as a lever for revenue growth. Risks include a dip in comparable-store sales and margin pressure that could temper gains. Valuation remains rich at about 37x earnings versus a sector average of 21.2x and a fair multiple of 31.8x, prompting questions whether the premium is justified or if momentum has already priced in future upside.
  • Ensurge Micropower ASA launches NOK 100 million private placement at NOK 0.90 per share; potential subsequent offering
    November 9, 2025, 5:46 PM EST. Ensurge Micropower ASA has announced a private placement aiming to raise NOK 100 million at a subscription price of NOK 0.90 per share. A possible subsequent offering could add up to NOK 20 million at the same price, pending approval at an upcoming Extraordinary General Meeting expected around 2 December 2025. The terms and record dates are: last day including right 7 November 2025; ex-date 10 November 2025; record date 11 November 2025. The prospectus for the Subsequent Offering will be published for approval by the Norwegian Financial Supervisory Authority. The move is disclosed under the Continuing Obligations.
  • Pony AI (PONY) Valuation After Share Price Slide
    November 9, 2025, 5:44 PM EST. Pony AI (Pony AI (PONY)) has seen its shares slide about 25% in the past month, with a 30-day return of -30.8%, fueling investor skepticism about near-term profitability. The stock trades at a price-to-book ratio of 7.1, well below peers at 13.1 but above the industry average of 3.7, highlighting a split between value versus sector pricing. A DCF-based fair value of $21.75 contrasts with the current price of $14.04, suggesting upside of over 35% if earnings power materializes. Ongoing net losses and sector volatility are key risks, even as the setup signals undervalued relative to peers. Investors must weigh whether the pullback reflects overhangs that may persist.
  • Ensurge Micropower ASA raises NOK 100m in private placement; insiders allocated shares
    November 9, 2025, 5:32 PM EST. Ensurge Micropower ASA announced a private placement raising NOK 100 million at NOK 0.90 per share. The deal allocated shares to primary insiders and close associates: AS Mascot Holding (close to Chairman Alexander Munch-Thore), Coretech AS (close to Board member Thomas Ramm), Nina Riibe (Board member), Shauna McIntyre (CEO), and Lars Eikeland (CFO). The disclosure follows section 5-12 of the Norwegian Securities Trading Act. Attachments provide the forms with transaction details.
  • TransUnion (TRU) Valuation: Stock Appears Undervalued vs. $106.70 Fair Value
    November 9, 2025, 5:30 PM EST. TransUnion (TRU) has rallied 3.7% over the last month but remains down about 24% year to date, with a positive three-year return. The stock trades at a hefty multiple (37.2x) vs. the industry average (24.5x) and its own fair value around 31.5x, setting up a debate on growth expectations. Our latest fair value estimate places a target of $106.70, suggesting the shares are undervalued at current levels. Key drivers include AI and ML investments and the rollout of the OneTru cloud-native platform, which support faster product launches, stronger cross-sell and higher operating leverage as costs ease post-2025. Risks to watch include regulatory pressure and rising competition from new entrants. The bullish case hinges on margin expansion and earnings upgrades beyond sector trends.
Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead
Previous Story

Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

ARCC Stock Today: Ares Capital’s 9.5% Dividend, Q3 Record NAV, and Fresh Insider Buying (Nov. 9, 2025)
Next Story

ARCC Stock Today: Ares Capital’s 9.5% Dividend, Q3 Record NAV, and Fresh Insider Buying (Nov. 9, 2025)

Related Articles

Go toTop